Hemostemix Inc. (HMTXF)
USD 0.07
(2.96%)
USD 0.07
(2.96%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.68 Million CAD | 6.23% |
| 2022 | 7.23 Million CAD | 23.73% |
| 2021 | 5.84 Million CAD | 70.87% |
| 2020 | 3.42 Million CAD | -17.54% |
| 2019 | 4.14 Million CAD | 253.31% |
| 2018 | 1.17 Million CAD | 152.68% |
| 2017 | 464.79 Thousand CAD | -87.4% |
| 2016 | 3.68 Million CAD | 492.45% |
| 2015 | 622.72 Thousand CAD | 12.87% |
| 2014 | 551.7 Thousand CAD | 127.05% |
| 2013 | 242.98 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.6 Million CAD | 8.37% |
| 2024 Q1 | 7.93 Million CAD | 3.28% |
| 2023 FY | 7.68 Million CAD | 6.23% |
| 2023 Q1 | 7.48 Million CAD | 3.46% |
| 2023 Q4 | 7.68 Million CAD | 1.74% |
| 2023 Q3 | 7.55 Million CAD | 5.06% |
| 2023 Q2 | 7.18 Million CAD | -3.93% |
| 2022 Q3 | 5.08 Million CAD | -5.46% |
| 2022 FY | 7.23 Million CAD | 23.73% |
| 2022 Q1 | 6.86 Million CAD | 17.37% |
| 2022 Q2 | 5.38 Million CAD | -21.59% |
| 2022 Q4 | 7.23 Million CAD | 42.2% |
| 2021 Q1 | 2.48 Million CAD | -27.36% |
| 2021 FY | 5.84 Million CAD | 70.87% |
| 2021 Q2 | 4.56 Million CAD | 83.6% |
| 2021 Q4 | 5.84 Million CAD | 26.66% |
| 2021 Q3 | 4.61 Million CAD | 1.15% |
| 2020 Q1 | 2.69 Million CAD | -35.13% |
| 2020 Q2 | 3.24 Million CAD | 20.68% |
| 2020 Q3 | 4.26 Million CAD | 31.39% |
| 2020 Q4 | 3.42 Million CAD | -19.82% |
| 2020 FY | 3.42 Million CAD | -17.54% |
| 2019 Q3 | 3.27 Million CAD | 78.85% |
| 2019 Q2 | 1.83 Million CAD | 35.98% |
| 2019 FY | 4.14 Million CAD | 253.31% |
| 2019 Q1 | 1.34 Million CAD | 14.75% |
| 2019 Q4 | 4.14 Million CAD | 26.6% |
| 2018 Q2 | 843.81 Thousand CAD | -2.65% |
| 2018 FY | 1.17 Million CAD | 152.68% |
| 2018 Q1 | 866.81 Thousand CAD | 86.49% |
| 2018 Q3 | 799.45 Thousand CAD | -5.26% |
| 2018 Q4 | 1.17 Million CAD | 46.91% |
| 2017 Q4 | 464.79 Thousand CAD | -4.49% |
| 2017 Q2 | 3.58 Million CAD | 11.45% |
| 2017 Q3 | 486.64 Thousand CAD | -86.44% |
| 2017 Q1 | 3.21 Million CAD | -12.74% |
| 2017 FY | 464.79 Thousand CAD | -87.4% |
| 2016 Q3 | 2.58 Million CAD | 75.58% |
| 2016 FY | 3.68 Million CAD | 492.45% |
| 2016 Q4 | 3.68 Million CAD | 42.99% |
| 2016 Q2 | 1.46 Million CAD | 70.53% |
| 2016 Q1 | 861.74 Thousand CAD | 38.38% |
| 2015 Q3 | 517.94 Thousand CAD | -13.03% |
| 2015 Q1 | 496.54 Thousand CAD | -10.0% |
| 2015 Q2 | 595.56 Thousand CAD | 19.94% |
| 2015 FY | 622.72 Thousand CAD | 12.87% |
| 2015 Q4 | 622.72 Thousand CAD | 20.23% |
| 2014 Q3 | 20.57 Thousand CAD | -71.33% |
| 2014 FY | 551.7 Thousand CAD | 127.05% |
| 2014 Q1 | 10 Thousand CAD | -53.69% |
| 2014 Q4 | 551.7 Thousand CAD | 2582.08% |
| 2014 Q2 | 71.75 Thousand CAD | 617.51% |
| 2013 Q4 | 21.59 Thousand CAD | -8.17% |
| 2013 Q3 | 23.51 Thousand CAD | -22.6% |
| 2013 Q1 | 10.99 Thousand CAD | -50.11% |
| 2013 FY | 242.98 Thousand CAD | 0.0% |
| 2013 Q2 | 30.38 Thousand CAD | 176.33% |
| 2012 Q3 | 26 Thousand CAD | 0.0% |
| 2012 Q4 | 22.03 Thousand CAD | -15.24% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | 84.711% |
| Skye Bioscience, Inc. | 14.07 Million USD | 45.389% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 86.978% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -850.179% |
| Qrons Inc. | 1.48 Million USD | -416.217% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -17093.917% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 18.814% |
| BioStem Technologies, Inc. | 15.9 Million USD | 51.681% |
| Regen BioPharma, Inc. | 5.45 Million USD | -40.812% |
| CSL Limited | 18.62 Billion USD | 99.959% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 89.742% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 89.396% |
| Rebus Holdings, Inc. | 5.24 Million USD | -46.604% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -27913.681% |
| Neon Bloom, Inc. | 1.22 Million USD | -526.726% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -3721.174% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 85.583% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 19.798% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1722.955% |
| SQZ Biotechnologies Company | 50.03 Million USD | 84.642% |
| Intellipharmaceutics International Inc. | 12 Million USD | 36.005% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -99.536% |
| Mesoblast Limited | 188.44 Million USD | 95.922% |
| Marizyme, Inc. | 26.67 Million USD | 71.191% |
| Genus plc | 485 Million USD | 98.415% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -31.533% |
| Pharming Group N.V. | 244.07 Million USD | 96.851% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -282.313% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -205.405% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -102.237% |
| ContraFect Corporation | 32.53 Million USD | 76.376% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -287.875% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -100.776% |
| IMV Inc. | 37.93 Million USD | 79.741% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 34.752% |
| MultiCell Technologies, Inc. | 1617.67 USD | -474965.557% |
| ONE Bio Corp. | 27.49 Million USD | 72.05% |
| Accustem Sciences Inc. | 1.07 Million USD | -612.075% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 90.073% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -263.345% |
| Q BioMed Inc. | 8.13 Million USD | 5.508% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 90.734% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -49.338% |
| Biomind Labs Inc. | 1.49 Million USD | -412.807% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 93.527% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 15.01% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 58.241% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -435.965% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -5308.349% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -33.749% |
| GB Sciences, Inc. | 5.41 Million USD | -41.853% |
| Alpha Cognition Inc. | 7.16 Million USD | -7.261% |
| HST Global, Inc. | 593.59 Thousand USD | -1194.657% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -510.311% |
| Halberd Corporation | 728.71 Thousand USD | -954.589% |
| Enzolytics Inc. | 365.26 Million USD | 97.896% |
| Agentix Corp. | 2.51 Million USD | -206.107% |
| Resverlogix Corp. | 67.39 Million USD | 88.597% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -816.263% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.273% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -348.366% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 68.945% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 35.437% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -109.677% |
| AVAX Technologies, Inc. | 3.99 Million USD | -92.426% |
| Zenith Capital Corp. | 27.56 Thousand USD | -27775.487% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.42% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -3120.14% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -105.794% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1028.762% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -183.407% |
| Kadimastem Ltd | 3.5 Million USD | -119.266% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -11382.307% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1553.757% |
| LadRx Corporation | 2.2 Million USD | -249.234% |
| Cell Source, Inc. | 15.8 Million USD | 51.381% |
| Regen BioPharma, Inc. | 5.45 Million USD | -40.812% |
| NovAccess Global Inc. | 7.86 Million USD | 2.236% |
| Affymax, Inc. | 8.87 Million USD | 13.369% |
| Itoco Inc. | 1.65 Million USD | -364.869% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -274.592% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -27.046% |
| Mobile Lads Corp. | 1.31 Million USD | -485.079% |
| CytoDyn Inc. | 127.89 Million USD | 93.991% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -18285.591% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -390.622% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 30.423% |
| SYBLEU INC | 681.41 Thousand USD | -1027.803% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -25.944% |
| International Stem Cell Corporation | 5.27 Million USD | -45.632% |
| Bioxytran, Inc. | 3.24 Million USD | -136.498% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1128.009% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -66.445% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 81.254% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 65.484% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -279.433% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -40.288% |
| Neutra Corp. | 973.52 Thousand USD | -689.395% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 73.514% |
| PureTech Health plc | 125.58 Million USD | 93.881% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -104.545% |
| IXICO plc | 1.9 Million USD | -304.411% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 62.565% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 92.562% |
| CSL Limited | 18.62 Billion USD | 99.959% |
| Cellectis S.A. | 249.36 Million USD | 96.918% |